The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome: a randomized, placebo-controlled, double-blind study

Autor: Robinson Joannides, Béatrice Morio, Alessandra Bura-Rivière, Jacques Amar, Julie Malloizel-Delaunay, Frédéric Bounoure, A.-F. Cailleux, Jean-Paul Rigaudière, Brigitte Laillet, Michele Iacob, Anne Blanchard, Christelle Monteil, Bruno Pannier, Aude Coquard, Erwan Bozec, Cathy Vendeville, Hakim Khettab, Bellien Jeremy, Nathalie Donnadieu, Alain Mercier, Mohamed Skiba, Léopold Fezeu, Jean-Michel Chardigny, Pierre Boutouyrie
Rok vydání: 2021
Předmět:
Zdroj: The American journal of clinical nutrition. 115(3)
ISSN: 1938-3207
Popis: BACKGROUND The effects of a dietary supplementation with the vegetable omega-3 α-linolenic acid (ALA) on cardiovascular homeostasis are unclear. In this context, it would be interesting to assess the effects of camelina oil. OBJECTIVE This study aimed to assess the cardiovascular and metabolic effects of camelina oil in hypertensive patients with metabolic syndrome. METHODS In a double-blind placebo-controlled randomized study, treated essential hypertensive patients with metabolic syndrome received during 6 months either cyclodextrin-complexed camelina oil containing ≈ 1.5 g ALA/day (n = 40), or an isocaloric placebo (n = 41), consisting in the same quantity of cyclodextrins and wheat starch. Anthropometric data, plasma lipids, glycemia, insulinemia, creatininemia, thiobarbituric acid reactive substances, high-sensitivity C-reactive protein, and n-3, n-6 and n-9 fatty acids in erythrocyte membranes were measured. Peripheral and central blood pressures, arterial stiffness, carotid intima-media thickness and brachial artery endothelium-dependent flow-mediated dilatation and endothelium-independent dilatation were assessed. RESULTS Compared to placebo, camelina oil increased ALA (mean ± SD: 0 ± 0.04 vs. 0.08 ± 0.06%, P
Databáze: OpenAIRE